Merck & Co. (NYSE:MRK) shares traded lower on Tuesday, tracking a broader market downturn as major indices slipped into the red.
The company said it has commenced a cash tender offer, through a subsidiary, to acquire all outstanding shares of Terns Pharmaceuticals Inc. (NASDAQ:TERN). The offer follows a definitive agreement announced March 25, 2026.
Under the terms, Merck is offering $53.00 per share in cash for Terns. The tender offer is set to expire May 4, 2026, subject to customary conditions, including shareholder participation thresholds and regulatory approvals.
The broader market is experiencing a downturn, with the S&P 500 down 0.9% and the Healthcare sector also facing a decline of 0.5%.
Technical Analysis
At $117.40, the stock is trading slightly above its 20-day simple moving average (SMA) by 0.04%, indicating a neutral short-term trend. However, it is trading 0.1% below its 50-day SMA, suggesting some weakness in the intermediate trend.
The relative strength index (RSI) is at 61.12, which is neutral, indicating that the stock is neither overbought nor oversold at this time. The moving average convergence divergence (MACD) shows a bullish signal, with the MACD line at 0.9163 above the signal line at 0.4374, suggesting upward momentum.
- Key Resistance: $125.00 — This level may act as a barrier for upward movement.
- Key Support: $114.00 — …
This post was originally published here